CN115120561B - Combined medicine metal organic hybridization nano assembly and application thereof - Google Patents
Combined medicine metal organic hybridization nano assembly and application thereof Download PDFInfo
- Publication number
- CN115120561B CN115120561B CN202210769044.5A CN202210769044A CN115120561B CN 115120561 B CN115120561 B CN 115120561B CN 202210769044 A CN202210769044 A CN 202210769044A CN 115120561 B CN115120561 B CN 115120561B
- Authority
- CN
- China
- Prior art keywords
- drug
- medicine
- assembly
- hybrid nano
- combined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 170
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 11
- 239000002184 metal Substances 0.000 title claims abstract description 11
- 238000009396 hybridization Methods 0.000 title description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 33
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 14
- 230000003993 interaction Effects 0.000 claims abstract description 5
- 229960004556 tenofovir Drugs 0.000 claims description 59
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 59
- 229940000425 combination drug Drugs 0.000 claims description 48
- 229960001997 adefovir Drugs 0.000 claims description 34
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 24
- 208000002672 hepatitis B Diseases 0.000 claims description 11
- 239000003443 antiviral agent Substances 0.000 claims description 10
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 8
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 5
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 229960001627 lamivudine Drugs 0.000 claims description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229960004245 silymarin Drugs 0.000 claims description 4
- 235000017700 silymarin Nutrition 0.000 claims description 4
- 229960005311 telbivudine Drugs 0.000 claims description 4
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
- -1 dicyclo-alcohol Chemical compound 0.000 claims description 3
- 229960003720 enoxolone Drugs 0.000 claims description 3
- 229960000980 entecavir Drugs 0.000 claims description 3
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
- PITRRWWILGYENJ-UHFFFAOYSA-N 2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCO)C=C1 PITRRWWILGYENJ-UHFFFAOYSA-N 0.000 claims description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims description 2
- 108010058907 Tiopronin Proteins 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229940091250 magnesium supplement Drugs 0.000 claims description 2
- 229960001639 penicillamine Drugs 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical group 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229960004402 tiopronin Drugs 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 claims 1
- 229940083466 soybean lecithin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 111
- 230000000694 effects Effects 0.000 abstract description 17
- 238000001727 in vivo Methods 0.000 abstract description 17
- 230000000973 chemotherapeutic effect Effects 0.000 abstract description 7
- 230000002035 prolonged effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 3
- 230000001360 synchronised effect Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000000429 assembly Methods 0.000 description 43
- 239000000243 solution Substances 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 41
- 206010028980 Neoplasm Diseases 0.000 description 28
- 238000000338 in vitro Methods 0.000 description 28
- 238000000502 dialysis Methods 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 20
- 206010021143 Hypoxia Diseases 0.000 description 18
- 238000012512 characterization method Methods 0.000 description 17
- 230000007954 hypoxia Effects 0.000 description 17
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000002245 particle Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 230000002757 inflammatory effect Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 12
- 238000011835 investigation Methods 0.000 description 12
- 210000005228 liver tissue Anatomy 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 229940044683 chemotherapy drug Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 8
- 238000011740 C57BL/6 mouse Methods 0.000 description 8
- 102100036250 GPI mannosyltransferase 4 Human genes 0.000 description 8
- 101001074618 Homo sapiens GPI mannosyltransferase 4 Proteins 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 7
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000007400 DNA extraction Methods 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000003034 chemosensitisation Effects 0.000 description 4
- 239000006114 chemosensitizer Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000311 effect on hepatitis Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000005917 in vivo anti-tumor Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002539 nanocarrier Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 229940126586 small molecule drug Drugs 0.000 description 4
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 4
- 229940075931 sodium dithionate Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- PDPJQWYGJJBYLF-UHFFFAOYSA-J hafnium tetrachloride Chemical compound Cl[Hf](Cl)(Cl)Cl PDPJQWYGJJBYLF-UHFFFAOYSA-J 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000002445 liver protective agent Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960001445 alitretinoin Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002114 nanocomposite Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 208000037922 refractory disease Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 238000000779 annular dark-field scanning transmission electron microscopy Methods 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- CUGMJFZCCDSABL-UHFFFAOYSA-N arsenic(3+);trisulfide Chemical compound [S-2].[S-2].[S-2].[As+3].[As+3] CUGMJFZCCDSABL-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical compound C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- CMOAHYOGLLEOGO-UHFFFAOYSA-N oxozirconium;dihydrochloride Chemical compound Cl.Cl.[Zr]=O CMOAHYOGLLEOGO-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a metal organic hybrid nano-assembly of a combined drug and application thereof, belonging to the technical field of biological medicine. The hybrid nano-assembly is formed by ionic interaction between a combined drug and metal ions; the combined medicine is a combination of an antiviral medicine and an anti-inflammatory liver-protecting medicine or a combination of a chemotherapeutic medicine and a chemotherapeutic sensitizer; the metal ion is selected from Mg 2+ 、Ca 2+ 、ZrO 2+ 、HfO 2+ 、Mn 2+ 、Fe 2+ 、Fe 3+ 、Cu 2+ 、Cu + 、Zn 2+ 、Pt 2+ 、Pt 4+ 、Pt 6+ 、Gd 3+ 、GdO + 、Ag + . The hybrid nano-assembly is prepared by simply mixing the organic components and the metal ions, so that the in-vivo half-life of the drug can be prolonged, the concentration of the drug at a focus part can be improved, the fixed drug proportion can be maintained, and synchronous pharmacokinetic and tissue distribution can be realized, thereby enhancing the synergistic treatment effect of the combined drug.
Description
Technical Field
The invention belongs to the technical field of biological medicine, and particularly relates to a metal organic hybrid nano-assembly of a combined medicine and application thereof.
Background
Clinical practice and exploratory studies in the last decade have shown that a single treatment modality is not effective in treating some physiologically complex refractory diseases. Thus, the methods of treatment for refractory diseases have shifted from monotherapy to combination therapy, increasing the efficiency of available treatment regimens. Combination therapy is a widely used disease treatment strategy that increases the possible therapeutic gain by combining existing disease-modifying therapies or new drugs, with acceptable theoretical basis, good safety and efficacy profiles. Combination therapy may alter different biological pathways, reduce the effective therapeutic dose required, reduce resistance, and reduce the overall cost of treatment.
Chronic hepatitis b is a chronic disease caused by infection with hepatitis b virus, and is currently incurable. Persistent hepatitis b virus infection causes liver inflammation, resulting in liver fibrosis and cirrhosis, and eventually, liver cancer is a life hazard. The nucleoside antiviral drugs widely used in clinic can effectively inhibit the replication of viruses for a long time to inhibit the exacerbation of hepatitis B, but are ineffective to treat chronic inflammation caused by virus invasion. Clinically, the intermittent administration of antiviral drugs and liver protection drugs is not an ideal combined administration mode, and needs to be improved. The co-delivery of antiviral and anti-inflammatory liver-protecting drug combinations for the combination treatment of chronic hepatitis b may ameliorate the deficiencies of existing therapeutic strategies.
Malignant tumors are a serious disease that threatens human health and life, and tumor stem-like cells (CSCs) are a heterogeneous cell with self-renewal and self-differentiation capabilities in tumor tissues. Studies have shown that CSCs are important factors in causing tumor chemotherapy resistance, recurrence and metastasis. In order to overcome tumor resistance, a combination treatment strategy of chemosensitizer and chemotherapeutic drug utilizes chemosensitizer to reduce the chemoresistance of resistant tumor, and shows enhanced therapeutic effect.
The realization of combination therapies requires the efficient integration of multiple therapeutic agents in a single carrier rather than simple mixing to produce beneficial synergistic therapeutic effects and maintain the specificity and persistence of the combination therapy. The rapidly evolving biomaterials and nanotechnology provide a research basis for co-delivery of co-drugs, making it possible to co-load several drugs into one delivery vehicle by simple physical adsorption or chemical interactions without loss of drug activity. The nano carrier can prolong the in vivo half-life of the medicine, is favorable for delivering the medicine to the focus part, enhances the treatment effect and reduces the toxic and side effects. The two medicaments are loaded in the same nano carrier, so that different medicaments are consistent in space and time in the treatment process, and synchronous pharmacokinetics and biological distribution are realized, and a synergistic treatment effect can be achieved. Although some nanocarriers (including liposomes, polymer nanoparticles, dendrimers, and inorganic nanoparticles) are currently developed for drug combination delivery, the problems of low drug loading rate, complex synthesis/preparation methods, and the like, which exist in practice, limit the application of the nanocarriers in combination drug delivery.
Therefore, there is still a need to develop a carrier platform with simple preparation method, high drug loading rate and capable of loading different combination drugs for co-delivery of the combination drugs.
Disclosure of Invention
The invention aims to provide a hybrid nano-assembly which is co-assembled by a combined drug and metal ions.
Another object of the present invention is to provide an application of the above hybrid nano-assembly in preparing a drug for treating chronic hepatitis b or tumor.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
the metal organic hybrid nano-assembly of the combined medicine is formed by interaction of positive and negative ions of the combined medicine and metal ions;
the combined medicine is the combination of antiviral medicine and anti-inflammatory liver-protecting medicine or the combination of chemotherapeutic medicine and chemotherapeutic sensitizer;
the metal ion is selected from Mg 2+ 、Ca 2+ 、ZrO 2+ 、HfO 2+ 、Mn 2+ 、Fe 2+ 、Fe 3+ 、Cu 2+ 、Cu + 、Zn 2+ 、Pt 2+ 、Pt 4+ 、Pt 6+ 、Gd 3+ 、GdO + Or Ag + ;
The medicine molecules of the antiviral medicine, the anti-inflammatory liver-protecting medicine, the chemotherapeutic medicine and the chemotherapeutic sensitizer contain phosphonic acid groups-PO 3 H 2 Or a phosphate group-OPO 3 H 2 Or modified with phosphate groups-OPO 3 H 2 。
In some embodiments, the antiviral drug is selected from tenofovir, entecavir, lamivudine, telbivudine, or adefovir.
In some embodiments, the anti-inflammatory liver protecting agent is selected from glycyrrhizic acid, glycyrrhetinic acid, magnesium isoglycyrrhetate, ammonium glycyrrhetate, diammonium glycyrrhetate, silymarin, bicyclo-ethanol, tiopronin, or penicillamine.
In some embodiments, the chemotherapeutic agent is selected from the group consisting of camptothecin, 10-hydroxycamptothecin, 7-ethyl-10-hydroxycamptothecin, irinotecan, topotecan, vinblastine, vincristine, vinorelbine, vindesine, cytarabine, gemcitabine, ancitabine, 5-fluorouracil, fluorodeoxyuridylic acid, 6-mercaptopurine, methotrexate, doxorubicin, epirubicin, doxorubicin, daunorubicin, mitoxantrone, paclitaxel, docetaxel, nimustine, teniposide, etoposide, aminoglutethimide, and melphalan.
In some embodiments, the chemosensitizer is selected from all-trans retinoic acid, 1, 3-cis retinoic acid, 9-cis retinoic acid, retinol, retinal, vitamin d, arsenic trioxide, arsenic sulfide, gossypol, quinidine, verapamil, chlorpromazine, cyclosporin a, reserpine, digoxin, amiodarone, progesterone, genistein, tamoxifen, felodipine, nifedipine, erythromycin, flufenamic acid, diltiazem, valpuidad, brinodad, exendid, oxazolidad, lovastatin, simvastatin, atorvastatin, rosuvastatin, curcumin, ginsenoside, eltrombopa, fumagillin C, lapatinib, novobiocin, sulfasalazine, or febuxostat.
In some embodiments, the drug molecule of the antiviral drug, anti-inflammatory liver protecting drug, chemotherapeutic sensitizer, and modified phosphate group-OPO 3 H 2 With a responsive linkage arm therebetween.
In some embodiments, the combination drug metal-organic hybrid nano-assembly further comprises a pharmaceutically acceptable adjuvant.
In some embodiments, the adjuvant is selected from polyethylene glycol, polyvinylpyrrolidone, poloxamer, polyvinyl alcohol, polyoxazoline, vitamin E polyethylene glycol succinate, cholesterol, soy lecithin, igepal CO-520, or cetyltrimethylammonium bromide.
The invention also provides application of the metal organic hybrid nano-assembly of the combined medicine in preparing a medicine for treating chronic hepatitis B, so as to be used for antiviral, anti-inflammatory and liver-protecting combined treatment of the chronic hepatitis B.
The invention also provides application of the metal organic hybrid nano-assembly of the combined medicine in preparing tumor treatment medicines, so as to treat common tumors or dry related drug-resistant tumors.
The metal organic hybrid nano assembly is a nano particle formed by assembling organic molecules and metal ions through ionic interaction, and the preparation method provided by the invention has the advantages of high drug loading capacity, simplicity in preparation and the like by taking the combined drug as an organic component and simply mixing the organic component and the metal ions. Because the phosphoric acid organic molecules and metal ions have strong acting force, the hybridized nano assembly is easy to form. In order to co-load the combination drug in the hybrid nano-assembly, it is desirable that the drug bear a phosphonic acid group (-PO) 3 H 2 ) Or a phosphate group (-OPO) 3 H 2 ) Or by chemically modifying the phosphate group (-OPO) 3 H 2 ) So that the hybrid nano-assembly can be assembled with metal ions to form the hybrid nano-assembly of the combined drug. As shown in fig. 1.
The combined medicine is co-carried in the nanometer assembly, so that the in vivo half-life period of the medicine can be prolonged, the concentration of the medicine at a focus part can be improved, the fixed medicine proportion can be maintained, and synchronous pharmacokinetics and tissue distribution can be realized, so that the synergistic treatment effect of the combined medicine is enhanced. Meanwhile, under the stimulation of focus microenvironment physiological signals (such as high-expression phosphatase, hypoxia, acid and high oxidation/reduction), the chemically modified phosphate group is subjected to responsive degradation to fall off, so that the proto-drug is released, and the activity of the drug is ensured.
Drawings
FIG. 1 is a schematic illustration of the preparation of hybrid drug combinations and their principle of responsive drug release.
FIG. 2 is a Transmission Electron Microscope (TEM) and high angle annular dark field scanning transmission electron microscope (HAADF-STEM) characterization of TFV/GAP/NA (Zr) in example 1.
FIG. 3 is a TEM characterization of AFV/SMP/NA (Fe) in example 1.
FIG. 4 shows in vitro drug delivery of TFV/GAP/NA (Zr), AFV/GAP/NA (Mg), AFV/SMP/NA (Fe) and TFV/SMP/NA (Cu) in example 1.
FIG. 5 shows the in vitro safety of TFV/GAP/NA (Zr) and AFV/SMP/NA (Fe) in example 1.
FIG. 6 shows the in vitro anti-inflammatory activity of TFV/GAP/NA (Zr) and AFV/SMP/NA (Fe) in example 1.
FIG. 7 shows in vitro antiviral activity of TFV/GAP/NA (Zr) and AFV/SMP/NA (Fe) in example 1.
FIG. 8 shows in vivo drug liver tissue distribution of TFV/GAP/NA (Zr) and AFV/SMP/NA (Fe) in example 1.
FIG. 9 shows in vivo antiviral activity of TFV/GAP/NA (Zr) and AFV/SMP/NA (Fe) in example 1.
FIG. 10 shows the in vivo anti-inflammatory activity of TFV/GAP/NA (Zr) and AFV/SMP/NA (Fe) in example 1.
FIG. 11 is a TEM characterization of LAMP/SMP/NA (Hf) in example 2.
FIG. 12 shows in vitro drug delivery of TFV/GAP/NA (Hf) and ETVP/SMP/NA (Hf) in example 2.
FIG. 13 is the in vitro safety profile of TFV/GAP/NA (Hf) and ETVP/SMP/NA (Hf) of example 2.
FIG. 14 shows the in vitro anti-inflammatory activity of TFV/GAP/NA (Hf) and ETVP/SMP/NA (Hf) of example 2.
FIG. 15 shows the in vitro antiviral activity of TFV/GAP/NA (Hf) and ETVP/SMP/NA (Hf) of example 2.
FIG. 16 shows in vivo drug liver tissue distribution of TFV/GAP/NA (Hf) and ETVP/SMP/NA (Hf) in example 2.
FIG. 17 shows in vivo antiviral activity of TFV/GAP/NA (Hf) and ETVP/SMP/NA (Hf) in example 2.
FIG. 18 shows the in vivo anti-inflammatory activity of TFV/GAP/NA (Hf) and ETVP/SMP/NA (Hf) of example 2.
FIG. 19 is TEM and HAADF-STEM characterization of r-ATRAP/Fdump/NA (Hf) of example 3.
FIG. 20 is an in vitro responsive drug delivery of r-ATRAP/Fdump/NA (Hf) and r-CRAP/r-CPTP/NA (Hf) in example 3.
FIG. 21 is an in vitro responsive drug delivery of r-ATRAP/Fdump/NA (Hf) and r-CRAP/r-CPTP/NA (Hf) in example 3.
FIG. 22 shows the in vitro antitumor activity of r-ATRAP/Fdump/NA (Hf) and r-CRAP/r-CPTP/NA (Hf) in example 3.
FIG. 23 shows the in vivo antitumor activity of r-ATRAP/Fdump/NA (Hf) and r-CRAP/r-CPTP/NA (Hf) in example 3.
FIG. 24 is a TEM characterization of r-VERP/r-CPTP/NA (Hf) in example 4.
FIG. 25 is an in vitro responsive drug delivery of r-VERP/r-CPTP/NA (Hf) and r-CSAP/r-DOXP/NA (Hf) in example 4.
FIG. 26 is an in vitro responsive drug delivery of r-VERP/r-CPTP/NA (Hf) and r-CSAP/r-DOXP/NA (Hf) in example 4.
FIG. 27 shows the in vitro antitumor Activity of r-VERP/r-CPTP/NA (Hf) and r-CSAP/r-DOXP/NA (Hf) in example 4.
FIG. 28 shows the in vivo antitumor activity of r-VERP/r-CPTP/NA (Hf) and r-CSAP/r-DOXP/NA (Hf) in example 4.
Detailed Description
The invention will now be described in further detail with reference to the drawings and specific examples, which should not be construed as limiting the invention. Modifications and substitutions to methods, procedures, or conditions of the present invention without departing from the spirit and nature of the invention are intended to be within the scope of the present invention. The experimental procedures and reagents not shown in the formulation of the examples were all in accordance with the conventional conditions in the art.
Example 1
Combined drug hybridization nano assembly for chronic hepatitis B combined treatment
1. Modification of antiviral and anti-inflammatory liver-protecting drugs
Entecavir, lamivudine or telbivudine (1.9 mmol) as antiviral agent was dissolved in 5mL trimethyl phosphate, and added to the nitrogen-protected reaction tube, phosphorus oxychloride (0.33 mL,3.8 mmol) was added dropwise to the above solution, and reacted at 4℃for 16h. After the reaction, 10mL of water was added to the reaction solution to quench the reaction, the mixture was stirred for 30min, the reaction solution was extracted 10 times with ethyl acetate, the aqueous phase was collected and mixed with methanol to spin dry, and an oily product was obtained. Purifying by column chromatography to obtain phosphorylated entecavir, lamivudine or telbivudine product.
Taking a 250mL reaction bottle, carrying out anhydrous drying and replacing nitrogen protection, dissolving phosphorus oxychloride (2 mL,14.6 mmol) in 60mL anhydrous tetrahydrofuran, adding the solution into the reaction bottle, adding a mixed solution of anti-inflammatory liver-protecting medicament glycyrrhetinic acid, silymarin or dicyclo alcohol (6.45 mmol) in 5.1mL anhydrous pyridine and 30mL anhydrous tetrahydrofuran dropwise under ice bath condition, keeping the temperature of 0 ℃ for reaction for 30min, and transferring to room temperature for reaction for 2h. After the reaction, the solvent was removed by rotary evaporation under reduced pressure, and the oily residue was dissolved in 100mL of methylene chloride, washed with 1M hydrochloric acid solution, washed with water, saturated brine, and the organic phase was collected and dried over anhydrous sodium sulfate. Filtering, removing solvent by rotary evaporation of organic phase to obtain oily crude product, and purifying by column chromatography to obtain phosphorylated glycyrrhetinic acid, silymarin or bicyclo-ethanol product.
2. Preparation of hybrid nano-assembly of combined medicine
The antiviral drug and the anti-inflammatory drug are mixed and assembled together with metal ions in aqueous solution to form the combined drug hybridized nano-assembly.
Tenofovir (TFV), adefovir (AFV) or phosphorylated Entecavir (ETVP) in 2% aqueous F-68 solution was formulated as 21mM solution A, and phosphorylated Glycyrrhetinic Acid (GAP) or phosphorylated Silymarin (SMP) in tetrahydrofuran was formulated as 18mM solution B. 1mL of the solution A and 0.2mL of the solution B are added dropwise into 1mL of 18mM zirconium oxychloride 2%F-68 water solution together, and after stirring for 15min, the combined drug hybrid nano-assembly TFV/GAP/NA (Zr), AFV/GAP/NA (Zr), ETVP/GAP/NA (Zr), TFV/SMP/NA (Zr), AFV/SMP/NA (Zr) or ETVP/SMP/NA (Zr) is prepared. The nano-assembly solution is placed in a dialysis bag and dialyzed in deionized water overnight to remove residual small molecule drugs and organic solvents. After dialysis, the solution was added to a centrifuge tube, centrifuged at high speed, the supernatant was discarded, and washed (re-suspension + washing) twice with deionized water. Finally, the nano-assemblies were resuspended in physiological saline and the particle size and polydispersity index (PDI) of the assemblies were characterized using a particle size analyzer, and the results are shown in table 1. TFV/GAP/NA (Zr) was selected for morphology characterization by Transmission Electron Microscopy (TEM) and for elemental mapping characterization by high angle annular dark field scanning transmission electron microscopy (HAADF-STEM), the results of which are shown in FIG. 2.
Table 1 particle size characterization of combination drug hybrid nano-assemblies
TFV, AFV or ETVP is dissolved in 3mL of water to prepare a solution of 0.3mM, added into 70mL of chloroform, 1.82g of cetyltrimethylammonium bromide and 3mL of n-hexanol are added, GAP or SMP is dissolved in 1mL of tetrahydrofuran to prepare a solution of 0.2mM, added into the solution, stirred for 30min at 35 ℃, and 1.6mL of MgCl with the concentration of 0.5M is added 2 (or CaCl) 2 、CuCl 2 、FeCl 3 ) The aqueous solution forms a hybrid nano-assembly body TFV/GAP/NA (Mg), AFV/GAP/NA (Mg), ETVP/GAP/NA (Ca), TFV/SMP/NA (Cu), AFV/SMP/NA (Fe) and ETVP/SMP/NA (Fe) of the combined medicament, and the mixed medicament is continuously stirred for 12 hours at room temperature, and is continuously centrifuged and resuspended for three times. Finally, the hybrid nano-assemblies were resuspended in physiological saline and the particle size and PDI of the assemblies were characterized by a particle size analyzer, the results of which are shown in table 2. AFV/SMP/NA (Fe) was selected for morphology characterization by TEM (FIG. 3).
Table 2 particle size characterization of combination drug hybrid nano-assemblies
3. Drug release of combination drug hybrid nano-assemblies
To simulate the drug release conditions at the liver site, 1mL of the combined drug hybrid nano-assembly (TFV/GAP/NA (Zr), AFV/GAP/NA (Mg), AFV/SMP/NA (Fe) or TFV/SMP/NA (Cu)) was added to the dialysis bag, while 1U/mL of phosphatase (simulating the hepatitis b high phosphatase environment) was added, the dialysis bag was sealed and immersed in 40mL of PBS release medium containing tween 80, sampled at fixed time points, the corresponding drug concentration was measured with LC-MS/MS, and the drug release amount was calculated. The drug release profile is shown in figure 4. Under the condition of simulating the liver high phosphatase level, the phosphatase hydrolyzes the phosphate group, and the antiviral drugs and the anti-inflammatory liver-protecting drugs in the hybrid nano-assembly can be quickly released.
4. In vitro safety and anti-inflammatory Activity assays for hybrid nanocomposites of combination drugs
1. In vitro safety investigation of hybrid nano-assemblies of combination drugs
RAW264.7 cells and L-02 cells were each used in 4X 10 cells per well 4 The density of individual cells was seeded in 96-well plates and after 24h of culture, the medium was aspirated. Serum-free medium containing hybrid nano-assemblies (TFV/GAP/NA (Zr) or AFV/SMP/NA (Fe)) with different drug concentrations was added, and incubated in a cell incubator for 24h and 48h, respectively, and the cell activity was detected with CCK-8 detection reagent. The cell viability results are shown in fig. 5, and after the hybrid nano-assemblies with different drug concentrations are incubated for 24 hours and 48 hours, the cell activity is not obviously reduced compared with that of the blank group, which indicates that the hybrid nano-assemblies of the combined drugs are all biosafety.
2. In vitro anti-inflammatory activity investigation of hybrid nano-assembly of combined drug
RAW264.7 cells were plated at 4X 10 per well 4 The density of individual cells was seeded in 96-well plates and after 24h of culture, the medium was aspirated. Serum-free medium containing hybrid nano-assemblies (TFV/GAP/NA (Zr) or AFV/SMP/NA (Fe), GAP or SMP 40. Mu.M) and LPS (1. Mu.g/mL) was added, after 24h incubation in an incubator, cell supernatants were collected, and after reasonable dilution, inflammatory factor levels were measured with TNF-alpha, IL-1. Beta. And IL-6ELISA kits to examine the in vitro anti-inflammatory activity of GAP. The in vitro anti-inflammatory results are shown in FIG. 6, where cells were addedThe level of inflammatory factors is obviously increased after LPS, and the level of inflammatory factors is obviously reduced after different combined drug hybridized nano-assemblies are added, which indicates that the combined drug hybridized nano-assemblies have good anti-inflammatory activity.
5. In vitro antiviral activity assay for hybrid nano-assemblies of combination drugs
HepG2.2.15 cells were used 4X 10 per well 4 The density of individual cells was seeded in 96-well plates and after 24h of culture, the medium was aspirated. Adding new culture medium containing hybridized nano assembly (TFV/GAP/NA (Zr) or AFV/SMP/NA (Fe)), incubating in incubator every 3 days, changing new culture medium containing medicine, observing cell state at 3, 6, 9 days, and sucking supernatant for HBV DNA assay. HBV DNA was extracted using a universal genomic DNA extraction kit and virus copy number detection was performed with Taqman probes in a CFX96 Real-time PCR detection system (Bio-Rad). The in vitro antiviral results are shown in figure 7, which shows that the hybrid nano-assemblies of the combination drugs have good continuous inhibition effect on hepatitis B virus.
6. In vivo pharmacokinetic investigation of combination drug hybrid nano-assemblies
C57BL/6 mice were randomly grouped into 10 groups of 10 mice each, tail vein injection combined drug hybrid nano-assembly formulations (TFV/GAP/NA (Zr) (TFV 6mg/kg, GAP 3 mg/kg)) or AFV/SMP/NA (Fe) (AFV 6mg/kg, SMP3 mg/kg)) and the corresponding free combined drug (tfv+gap or afv+smp), at predetermined interval time points, five mice per group were bled from the orbits, and the other five mice were bled at adjacent interval time points, and analysis was performed with LC-MS/MS system after sample treatment to determine the amount of drug. The pharmacokinetic parameters were calculated using a non-compartmental model of Phoenix WinNonlin kinetic software, and the results are shown in tables 3 and 4, wherein each parameter of the pharmacokinetics of the hybrid nano-assembly preparation group is obviously improved compared with the corresponding free drug group, and the in vivo half-life of the drug is obviously prolonged.
TABLE 3 pharmacokinetic parameters of TFV/GAP/NA (Zr) and free (TFV+GAP)
TABLE 4 pharmacokinetic parameters of AFV/SMP/NA (Fe) and free (AFV+SMP)
7. Liver tissue drug distribution investigation of combined drug hybrid nano-assembly
C57BL/6 mice were randomly grouped into 35 groups of each group, a combination drug hybrid nano-assembly preparation (TFV/GAP/NA (Zr) (TFV 6mg/kg, GAP 3 mg/kg)) or AFV/SMP/NA (Fe) (AFV 6mg/kg, SMP3 mg/kg)) and a free combination drug (tfv+gap or afv+smp) corresponding to the same concentration were injected into the tail vein, and at a predetermined time point, five mice were sacrificed in each group, livers were collected, 0.1g of liver tissues were weighed after washing, and after grinding treatment, drug concentration in the livers was measured by LC-MS/MS. As shown in fig. 8, the hybrid nano-assembly formulation group can significantly promote drug accumulation in the liver compared to the corresponding free drug.
8. In vivo antiviral activity investigation of hybrid nano-assembly of combined drug
The HBV gene transfected C57BL/6 mice were randomly grouped into 5 groups, and the combination drug hybrid nano-assembly preparation (TFV/GAP/NA (Zr) (TFV 6mg/kg, GAP 3 mg/kg) or AFV/SMP/NA (Fe) (AFV 6mg/kg, SMP3 mg/kg)) was administered once every three days for 15 consecutive days. At days 3, 6, 9, 12, 15 after the first dose, respectively, the mice orbits were bled and serum isolated, HBV DNA extraction was performed, and virus copy number detection was performed using Taqman probes in the CFX96 Real-time PCR detection system (Bio-Rad). On day 15, mice were sacrificed to collect livers, 0.1g of liver tissue was weighed, homogenized, centrifuged to collect supernatant, and HBV copy number in livers was determined by PCR method. As shown in FIG. 9, the continuous administration of the hybrid nano-assembly preparation can obviously inhibit HBV levels in blood and liver, which indicates that the hybrid nano-assemblies of the combined medicines have optimal continuous inhibition effect on hepatitis B virus.
9. Investigation of in vivo anti-inflammatory Activity of hybrid nano-Assembly of Combined drug
C57BL/6 mice were randomly grouped into 6 groups, and tail vein injection of the combination drug hybrid nano-assembly preparation (TFV/GAP/NA (Zr) (TFV 6mg/kg, GAP 3 mg/kg) or AFV/SMP/NA (Fe) (AFV 6mg/kg, SMP3 mg/kg)) was administered once every three days for 15 consecutive days. After 2 hours from the last administration, mice in the administration group were intraperitoneally injected with 0.2% carbon tetrachloride/corn oil solution at a carbon tetrachloride administration dose of 32mg/kg to induce an acute liver injury model. 20 hours after carbon tetrachloride injection, all mice were bled from the orbit, and the mice were sacrificed and liver tissue was collected. The collected blood samples were centrifuged and the supernatant serum was taken, after appropriate dilution, and inflammatory factor levels were measured using TNF- α, IL-1 β, and IL-6ELISA kits. After homogenizing liver tissue in 0.1g, TNF-alpha, IL-1 beta and IL-6ELISA kit are used to measure the level of inflammatory factor. As shown in fig. 10, after the liver injury is induced by carbon tetrachloride, the inflammatory factor level in blood and liver is obviously increased, and the pre-administration of the hybrid nano-assembly preparation obviously reduces the inflammatory factor level in blood and liver, which indicates that the hybrid nano-assembly of the combined medicines has the optimal anti-inflammatory and liver-protecting effects.
Example 2
Combined drug hybridization nano assembly for chronic hepatitis B combined treatment
1. Preparation of hybrid nano-assembly of combined medicine
The antiviral drug and the anti-inflammatory drug are mixed and assembled together with metal ions in aqueous solution to form the combined drug hybridized nano-assembly.
TFV, ETVP or phosphorylated Lafumipdine (LAMP) is dissolved in 2% PVP aqueous solution to prepare 21mM A solution, GAP or SMP is dissolved in tetrahydrofuran to prepare 18mM B solution, 1mL of A solution and 0.2mL of B solution are jointly dripped into 1mL of 18mM hafnium tetrachloride 2% PVP aqueous solution, and after stirring for 15min, the combined drug hybrid nano-assembly TFV/GAP/NA (Hf), ETVP/GAP/NA (Hf), LAMP/GAP/NA (Hf), TFV/SMP/NA (Hf), ETVP/SMP/NA (Hf) or LAMP/SMP/NA (Hf) is prepared, the assembly solution is placed in a dialysis bag, and residual small molecule drugs are removed by dialysis in deionized water overnight. The solution in the dialysis bag is centrifuged at a high speed and the white assembly nanoparticles are deposited on the bottom of the centrifuge tube. The supernatant was discarded, the precipitate was washed with deionized water and centrifuged twice. Finally, the hybrid nano-assembly of the combined drug was resuspended in physiological saline and the particle size of the assembly was characterized by a potentiometric particle size analyzer, and the results are shown in table 5. LAMP/SMP/NA (Hf) was chosen for morphology characterization by TEM (FIG. 11).
Table 5 particle size characterization of combination drug hybrid nano-assemblies
2. Drug release of combination drug hybrid nano-assemblies
1mL of the combined drug hybrid nano-assembly (TFV/GAP/NA (Hf) or ETVP/SMP/NA (Hf)) was added to a dialysis bag, 1U/mL of phosphatase (simulating the hepatitis B high phosphatase environment) was added at the same time, the dialysis bag was sealed and immersed in 40mL of PBS release medium containing Tween 80, sampling was performed at a fixed time point, the corresponding drug concentration was measured by LC-MS/MS, and the drug release amount was calculated. The drug release profile is shown in figure 12. Antiviral drugs and anti-inflammatory liver-protecting drugs in the hybrid nano-assembly can be gradually released under the condition of simulating the liver high phosphatase level.
3. In vitro safety and anti-inflammatory Activity assays for hybrid nanocomposites of combination drugs
1. In vitro safety investigation of hybrid nano-assemblies of combination drugs
RAW264.7 cells and L-02 cells were each used in 4X 10 cells per well 4 The density of individual cells was seeded in 96-well plates and after 24h of culture, the medium was aspirated. Serum-free medium containing hybridized nano-assemblies (TFV/GAP/NA (Hf) or ETVP/SMP/NA (Hf)) with different drug concentrations was added, and incubated in a cell incubator for 24h and 48h, respectively, and cell activity was detected with CCK-8 detection reagent. The cell viability results are shown in fig. 13, and after the hybrid nano-assemblies with different drug concentrations are incubated for 24h and 48h, the cell activity is not obviously reduced compared with that of the blank group, which indicates that the hybrid nano-assemblies of the combined drugs are all biosafety.
2. In vitro anti-inflammatory activity investigation of hybrid nano-assembly of combined drug
RAW264.7 cells were plated at 4X 10 per well 4 The density of individual cells was seeded in 96-well plates and after 24h of culture, the medium was aspirated. Serum-free medium containing hybrid nano-assemblies (TFV/GAP/NA (Hf) or ETVP/SMP/NA (Hf), GAP or SMP 40. Mu.M) and LPS (1. Mu.g/mL) was added, after 24h incubation in an incubator, cell supernatants were collected, and after reasonable dilution, inflammatory factor levels were measured using TNF-. Alpha., IL-1. Beta., IL-6ELISA kit to examine the in vitro anti-inflammatory activity of GAP. In vitro anti-inflammatory results are shown in fig. 14, the level of inflammatory factors is obviously increased after LPS is added into cells, and the level of inflammatory factors is obviously reduced after different combined drug hybridized nano-assemblies are added, so that the combined drug hybridized nano-assemblies have optimal anti-inflammatory activity.
4. In vitro antiviral activity assay for hybrid nano-assemblies of combination drugs
HepG2.2.15 cells were used 4X 10 per well 4 The density of individual cells was seeded in 96-well plates and after 24h of culture, the medium was aspirated. Adding new culture medium containing hybridized nano assembly (TFV/GAP/NA (Hf) or ETVP/SMP/NA (Hf), TFV or ETV being 154 μm), incubating in incubator every 3 days for new culture medium containing medicine, observing cell state at 3, 6, 9 days respectively, and sucking supernatant for HBV DNA assay analysis. HBV DNA was extracted using a universal genomic DNA extraction kit and virus copy number detection was performed with Taqman probes in a CFX96 Real-time PCR detection system (Bio-Rad). The in vitro antiviral results are shown in figure 15, which shows that the hybrid nano-assemblies of the combination drugs have the optimal sustained inhibition effect on hepatitis B virus.
5. In vivo pharmacokinetic investigation of combination drug hybrid nano-assemblies
The C57BL/6 mice were randomly grouped into 10 groups of 10 mice each, and the tail vein injection combination drug hybrid nano-assembly preparation (TFV/GAP/NA (Hf) (TFV 6mg/kg, GAP 3 mg/kg)) or ETVP/SMP/NA (Hf) (ETVP 6mg/kg, SMP3 mg/kg)) and the corresponding free combination drug (tfv+gap or etv+smp), and at predetermined interval time points, the orbitals of five mice of each group were bled, and the other five mice were bled at adjacent interval time points, and analysis was performed by LC-MS/MS system after sample treatment to determine the amount of drug. The pharmacokinetic parameters were calculated using a non-compartmental model of Phoenix WinNonlin kinetic software, and the results are shown in tables 6 and 7, wherein each parameter of the pharmacokinetics of the hybrid nano-assembly preparation group is obviously improved compared with the corresponding free drug group, and the in vivo half-life of the drug is obviously prolonged.
TABLE 6 pharmacokinetic parameters of TFV/GAP/NA (Hf) and free (TFV+GAP)
TABLE 7 pharmacokinetic parameters of ETVP/SMP/NA (Hf) and free (ETV+SMP)
6. Liver tissue drug distribution investigation of combined drug hybrid nano-assembly
C57BL/6 mice were randomly grouped into 35 groups of each group, a combination drug hybrid nano-assembly preparation (TFV/GAP/NA (Hf) (TFV 6mg/kg, GAP 3 mg/kg)) or ETVP/SMP/NA (Hf) (ETVP 6mg/kg, SMP3 mg/kg)) and a free combination drug (tfv+gap or etvp+smp) corresponding to the same concentration were injected into the tail vein, and at a predetermined time point, five mice were sacrificed in each group, livers were collected, 0.1g of liver tissues were weighed after washing, and after grinding treatment, drug concentration in the livers was measured by LC-MS/MS. As shown in fig. 16, the hybrid nano-assembly formulation group can significantly promote drug accumulation in the liver compared to the corresponding free drug.
7. In vivo antiviral activity investigation of hybrid nano-assembly of combined drug
HBV gene transfected C57BL/6 mice were randomly grouped into 5 groups, and the combination drug hybrid nano-assembly preparation (TFV/GAP/NA (Hf) (TFV 6mg/kg, GAP 3 mg/kg) or ETVP/SMP/NA (Hf) (ETVP 6mg/kg, SMP3 mg/kg)) was administered once every three days for 15 consecutive days. At days 3, 6, 9, 12, 15 after the first dose, respectively, the mice orbits were bled and serum isolated, HBV DNA extraction was performed, and virus copy number detection was performed using Taqman probes in the CFX96 Real-time PCR detection system (Bio-Rad). On day 15, mice were sacrificed to collect livers, 0.1g of liver tissue was weighed, homogenized, centrifuged to collect supernatant, and HBV copy number in livers was determined by PCR method. As shown in FIG. 17, the continuous administration of the hybrid nano-assembly preparation can obviously inhibit HBV levels in blood and liver, which indicates that the hybrid nano-assemblies of the combined medicaments have the optimal continuous inhibition effect on hepatitis B virus.
8. Investigation of in vivo anti-inflammatory Activity of hybrid nano-Assembly of Combined drug
The C57BL/6 mice were randomly grouped into 6 groups, and the tail vein injection combination drug hybrid nano-assembly preparation (TFV/GAP/NA (Hf) (TFV 6mg/kg, GAP 3 mg/kg) or ETVP/SMP/NA (Hf) (ETVP 6mg/kg, SMP3 mg/kg)) was administered once every three days for 15 consecutive days. After 2 hours from the last administration, mice in the administration group were intraperitoneally injected with 0.2% carbon tetrachloride/corn oil solution at a carbon tetrachloride administration dose of 32mg/kg to induce an acute liver injury model. 20 hours after carbon tetrachloride injection, all mice were bled from the orbit, and the mice were sacrificed and liver tissue was collected. The collected blood samples were centrifuged and the supernatant serum was taken, after appropriate dilution, and inflammatory factor levels were measured using TNF- α, IL-1 β, and IL-6ELISA kits. After homogenizing liver tissue in 0.1g, TNF-alpha, IL-1 beta and IL-6ELISA kit are used to measure the level of inflammatory factor. As shown in fig. 18, after the liver injury is induced by carbon tetrachloride, the inflammatory factor level in blood and liver is obviously increased, and the pre-administration of the hybrid nano-assembly preparation obviously reduces the inflammatory factor level in blood and liver, which indicates that the hybrid nano-assembly of the combined medicines has the optimal anti-inflammatory and liver-protecting effects.
Example 3
Combined drug hybridized nano assembly for drug-resistant tumor combined treatment
1. Modification of chemotherapeutic drugs and chemosensitizer/differentiation inducer
Chemotherapeutic drug modification
5-fluoro-2' -deoxyuridine, camptothecin, doxorubicin or taxol (1.9 mmol) were dissolved in 5mL trimethyl phosphate, added to a nitrogen-protected reaction tube, phosphorus oxychloride (0.33 mL,3.8 mmol) was added dropwise to the above solution, and reacted at 4℃for 16h. After the reaction, 10mL of water was added to the reaction solution to quench the reaction, the mixture was stirred for 30min, the reaction solution was extracted 10 times with ethyl acetate, the aqueous phase was collected and mixed with methanol to spin dry, and an oily product was obtained. Column chromatography gives the phosphorylated product.
Phosphorylated hypoxia responsive differentiation inducer synthesis
All-trans retinoic acid, 1, 3-cis retinoic acid or 9-cis retinoic acid (10 mmol) was dissolved in a mixed solution of 100mL of methylene chloride and 6mL of dimethyl sulfoxide, 4- (4- (hydroxymethyl) phenyl) diazenyl) phenol (3.16 g,10 mmol), 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (2.4 g,12 mmol), 1-hydroxybenzotriazole (1.62 g,12 mmol), N, N-diisopropylethylamine (5 mL) was added and reacted overnight at room temperature. After the reaction is finished, the reaction liquid is washed with water, saturated brine is washed with water, anhydrous sodium sulfate is dried, an organic phase is dried by spin to obtain a crude product, and the azobenzene modified product is obtained by column chromatography.
Phosphorus oxychloride (0.2 mL,2.3 mmol) was dissolved in 2mL of anhydrous THF, added to a nitrogen-protected reaction tube and placed under an ice-water mixed bath at 0 ℃, and a mixed solution of azobenzene-modified differentiation inducer (0.67 mmol) dissolved in anhydrous pyridine (0.53 mL,6.5 mmol) and 3mL of anhydrous THF was added dropwise to the above reaction solution to react at 0℃for 3 hours. After the reaction, the reaction solution is dried by spin, the residue is dissolved in ethyl acetate, the organic phase is washed by water, diluted hydrochloric acid solution is washed by saturated saline water, the organic phase is dried by anhydrous sodium sulfate and filtered, and the crude product is obtained by spin drying. Column chromatography gives phosphorylated hypoxia response product.
2. Preparation of hybrid nano-assembly of combined medicine
Fluorodeoxyuridylic acid (FdUMP), active oxygen responsive phosphorylated camptothecin (r-CPTP) or phosphorylated doxorubicin (r-DOXP) was dissolved in 5ml of a 2% TPGS solution to prepare a 15mM solution, and the pH was adjusted to weak alkaline (ph=8) with sodium hydroxide solution. Phosphorylated hypoxia-responsive all-trans retinoic acid (r-ATRAP) or 1, 3-cis retinoic acid (r-CRAP) is dissolved in 1mL of ethanol to prepare a 76mM solution, and 2mL of 3mM hafnium tetrachloride 2% TPGS solution is added into the solution in a dropwise manner, and after stirring for 15min, a combined drug hybrid nano-assembly (r-ATRAP/Fdump/NA (Hf), r-ATRAP/r-CPTP/NA (Hf), r-ATRAP/r-DOXP/NA (Hf), r-CRAP/Fdump/NA (Hf), r-CRAP/r-CPTP/NA (Hf) or r-CRAP/r-DOXP/NA (Hf)) is formed. The assembly solution was placed in a dialysis bag and dialyzed overnight in deionized water to remove residual small molecule drug. After washing three times by continuous centrifugation, the assembly was suspended in physiological saline, and the particle size of the assembly was characterized by an potentiometric particle size analyzer, and the results are shown in Table 8. The r-ATRAP/FdUMP/NA (Hf) was selected for morphology characterization by TEM and element mapping characterization by HAADF-STEM, and the results are shown in FIG. 19.
Table 8 particle size characterization of combination drug hybrid nano-assemblies
3. Drug release of combination drug hybrid nano-assemblies
1mL of the combined drug hybrid nano-assembly (r-ATRAP/FdUMP/NA (Hf) or r-CRAP/r-CPTP/NA (Hf)) was added to a dialysis bag, 10mM sodium dithionate (simulating a hypoxia environment) was added at the same time, the dialysis bag was sealed and immersed in 40mL of PBS release medium containing Tween 80, samples were taken at fixed time points, the corresponding drug concentrations were measured by HPLC, and the drug release amounts were calculated. The drug release profile is shown in figure 20. Under the condition of simulating tumor hypoxia, the hypoxia-responsive drugs in the assembly are released rapidly, and the chemotherapeutic drugs are released slowly.
1mL of the combination drug hybrid nano-assembly (r-ATRAP/FdUMP/NA (Hf) or r-CRAP/r-CPTP/NA (Hf)) was added to the dialysis bag, 10mM sodium dithionate was added at the same time, and the dialysis bag was sealed and immersed in 40mL of Tween 80-containing PBS release medium, and samples were taken at fixed time points. After 12h of release, hydrogen peroxide is added into the dialysis bag, the dialysis bag is placed into a release medium for continuous release, sampling is carried out at a fixed time point, the concentration of the corresponding medicine is measured by HPLC, and the release amount of the medicine is calculated. The drug release profile is shown in figure 21. Under the condition of simulating tumor hypoxia, the drugs with hypoxia response in the assembly are released rapidly, the chemotherapeutic drugs are released slowly, and the hydrogen peroxide is added to simulate the condition of active oxygen, so that the release of the chemotherapeutic drugs is obviously accelerated.
4. In vitro cytotoxicity assay of combination drug hybrid nano-assemblies on drug-resistant tumor cells
4T1 CSCs were used 5X 10 per well 3 The density of individual cells was inoculated into 96-well ultra-low adhesion plates, hybrid nano-assemblies (r-ATRAP/FdUMP/NA (Hf) or r-CRAP/r-CPTP/NA (Hf)) containing different drug concentrations were added, and the cells were incubated in a hypoxia incubator for 48 hours, and the cell activity was detected using CCK-8 detection reagents. The cell viability results are shown in FIG. 22, and the IC50 values of r-ATRAP/FdUMP/NA (Hf) and r-CRAP/r-CPTP/NA (Hf) are 0.4274 and 0.3510 mu M respectively, which indicate that the hybrid nano-assemblies of the combined drugs reverse the drug resistance of tumor stem-like cells and have obvious killing effect.
5. In vivo antitumor activity assay of hybrid nano-assemblies of combination drugs
4T1 CSCs were collected and resuspended in a 1:1 volume ratio of PBS and Matrigel mixed solution at 5X 10 5 The density of individual cells/cells was inoculated under the left breast pad of the abdominal dehaired Balb/c mice to construct a drug resistant tumor mouse model. Tumor-bearing mice were randomly grouped into six groups, and the combination drug hybrid nano-assembly formulations (r-ATRAP/FdUMP/NA (Hf) (FdUMP 3.33mg/kg, r-ATRAP 24 mg/kg) or r-CRAP/r-CPTP/NA (Hf) (r-CPTP 3.33mg/kg, r-CRAP 24 mg/kg)) were administered by tail vein injection once every two days for 14 consecutive days. Tumor length and diameter were measured every two days, tumor volume was calculated, and tumor volume changes were detected. The results are shown in fig. 23, and the combined drug hybrid nano-assembly preparation group has the best tumor inhibition effect.
Example 4
Combined drug hybridized nano assembly for drug-resistant tumor combined treatment
1. Preparation of hybrid nano-assembly of combined medicine
The corresponding phosphorylated paclitaxel (r-PTXP) of r-CPTP, r-DOXP or active oxygen was dissolved in 5ml of 2% TPGS solution to prepare a solution with a concentration of 15mM, and pH was adjusted to be weakly alkaline (ph=8) with sodium hydroxide solution. Phosphorylated hypoxia-responsive verapamil (r-VERP) or cyclosporin A (r-CSAP) was dissolved in 1mL of ethanol to prepare a 76mM solution, and 2mL of a 3mM hafnium tetrachloride 2% TPGS solution was added dropwise thereto together, followed by stirring for 15min to form a combination drug hybrid nano-assembly (r-VERP/r-CPTP/NA (Hf), r-VERP/r-DOXP/NA (Hf), r-VERP/r-PTXP/NA (Hf), r-CSAP/r-CPTP/NA (Hf), r-CSAP/r-DOXP/NA (Hf) or r-CSAP/r-PTXP/NA (Hf)). The assembly solution was placed in a dialysis bag and dialyzed overnight in deionized water to remove residual small molecule drug. After washing three times by continuous centrifugation, the assembly was suspended in physiological saline, and the particle size was characterized by an potentiometric particle size analyzer, and the results are shown in Table 13. The morphology characterization was performed by TEM with r-VERP/r-CPTP/NA (Hf) and the results are shown in FIG. 24.
Table 13 particle size characterization of hybrid nano-assemblies of combination drugs
2. Drug release of combination drug hybrid nano-assemblies
1mL of the combined drug hybrid nano-assembly (r-VERP/r-CPTP/NA (Hf) or r-CSAP/r-DOXP/NA (Hf)) was added to a dialysis bag, 10mM sodium dithionate (simulating a hypoxia environment) was added at the same time, the dialysis bag was sealed and immersed in 40mL of PBS release medium containing Tween 80, samples were taken at fixed time points, the corresponding drug concentrations were measured by HPLC, and the drug release amounts were calculated. The drug release profile is shown in figure 25. Under the condition of simulating tumor hypoxia, the hypoxia-responsive drugs in the assembly are released rapidly, and the chemotherapeutic drugs are released slowly.
1mL of the combination drug hybrid nano-assembly (r-VERP/r-CPTP/NA (Hf) or r-CSAP/r-DOXP/NA (Hf)) was added to the dialysis bag, 10mM sodium dithionate (simulating a hypoxic environment) was added at the same time, and the dialysis bag was sealed and immersed in 40mL of PBS release medium containing Tween 80, and samples were taken at fixed time points. After 12h of release, hydrogen peroxide is added into the dialysis bag, the dialysis bag is placed into a release medium for continuous release, sampling is carried out at a fixed time point, the concentration of the corresponding medicine is measured by HPLC, and the release amount of the medicine is calculated. The drug release profile is shown in figure 26. Under the condition of simulating tumor hypoxia, the drugs with hypoxia response in the assembly are released rapidly, the chemotherapeutic drugs are released slowly, and the hydrogen peroxide is added to simulate the condition of active oxygen, so that the release of the chemotherapeutic drugs is obviously accelerated.
3. In vitro cytotoxicity assay of combination drug hybrid nano-assemblies on drug-resistant tumor cells
4T1 CSCs were used 5X 10 per well 3 The density of individual cells was inoculated into 96-well ultra-low adhesion plates, hybrid nano-assemblies (r-VERP/r-CPTP/NA (Hf) or r-CSAP/r-DOXP/NA (Hf)) containing different drug concentrations were added, placed in a hypoxia incubator for 48h, and cell activity was detected using CCK-8 detection reagents. The cell viability results are shown in FIG. 27, and the IC50 values of r-VERP/r-CPTP/NA (Hf) and r-CSAP/r-DOXP/NA (Hf) are 0.5293 and 0.1731 mu M respectively, which indicate that the hybrid nano-assemblies of the combined drugs reverse the drug resistance of tumor stem-like cells and have obvious killing effect.
4. In vivo antitumor activity assay of hybrid nano-assemblies of combination drugs
4T1 CSCs were collected and resuspended in a 1:1 volume ratio of PBS and Matrigel mixed solution at 5X 10 5 The density of individual cells/cells was inoculated under the left breast pad of the abdominal dehaired Balb/c mice to construct a drug resistant tumor mouse model. Tumor-bearing mice were randomly grouped into six groups, and the combination drug hybrid nano-assembly formulations (r-VERP/r-CPTP/NA (Hf) (r-CPTP 4mg/kg, r-VERP 24 mg/kg) or r-CSAP/r-DOXP/NA (Hf) (r-DOXP 4mg/kg, r-CSAP 24 mg/kg)) were administered once every two days for 14 consecutive days. Tumor length and diameter were measured every two days, tumor volume was calculated, and tumor volume changes were detected. The results are shown in fig. 28, where the combination drug hybrid nano-assembly formulation group had the optimal tumor suppression effect.
In addition to the implementations described above, other implementations of the invention are possible. All technical schemes formed by equivalent substitution or equivalent transformation fall within the protection scope of the invention.
Claims (4)
1. The metal organic hybrid nano-assembly of the combined medicine is characterized in that: is formed by ionic interaction between a combination drug and metal ions;
the combined medicine is a combination of an antiviral medicine and an anti-inflammatory liver-protecting medicine;
the metal ion is selected from Mg 2+ 、Ca 2+ 、ZrO 2+ 、HfO 2+ 、Mn 2+ 、Fe 2+ 、Fe 3+ 、Cu 2+ 、Cu + 、Zn 2+ 、Pt 2+ 、Pt 4+ 、Pt 6+ 、Gd 3+ 、GdO + 、Ag + ;
The medicine molecule of the antiviral medicine and the anti-inflammatory liver-protecting medicine contains phosphonic acid group-PO 3 H 2 Or a phosphate group-OPO 3 H 2 Or after chemical modification contains phosphate group-OPO 3 H 2 ;
The antiviral drug is selected from tenofovir, entecavir, lamivudine, telbivudine or adefovir;
the anti-inflammatory and liver-protecting medicine is selected from glycyrrhizic acid, glycyrrhetinic acid, magnesium isoglycyrrhetate, ammonium glycyrrhizate, diammonium glycyrrhizate, silymarin, dicyclo-alcohol, tiopronin or penicillamine;
the medicine molecules of the antiviral medicine and the anti-inflammatory liver-protecting medicine and the modified phosphate group-OPO 3 H 2 With a responsive linkage arm therebetween.
2. The combination drug metal-organic hybrid nano-assembly according to claim 1, wherein: the metal organic hybrid nano-assembly of the combined medicine also contains pharmaceutically acceptable auxiliary materials.
3. The combination drug metal-organic hybrid nano-assembly according to claim 2, wherein: the pharmaceutically acceptable auxiliary materials are selected from polyethylene glycol, polyvinylpyrrolidone, poloxamer, polyvinyl alcohol, polyoxazoline, vitamin E polyethylene glycol succinate, cholesterol, soybean lecithin, igepal CO-520 or hexadecyl trimethyl ammonium bromide.
4. Use of the combination drug metal organic hybrid nano-assembly of claim 1 in the preparation of a medicament for the treatment of chronic hepatitis b.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210769044.5A CN115120561B (en) | 2022-06-30 | 2022-06-30 | Combined medicine metal organic hybridization nano assembly and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210769044.5A CN115120561B (en) | 2022-06-30 | 2022-06-30 | Combined medicine metal organic hybridization nano assembly and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115120561A CN115120561A (en) | 2022-09-30 |
CN115120561B true CN115120561B (en) | 2023-12-19 |
Family
ID=83381318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210769044.5A Active CN115120561B (en) | 2022-06-30 | 2022-06-30 | Combined medicine metal organic hybridization nano assembly and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115120561B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1518983A (en) * | 2003-01-22 | 2004-08-11 | 赖庆莲 | Coordinated modication combination for anti hepatitis B virus |
CN1895671A (en) * | 2005-12-08 | 2007-01-17 | 淮北市辉克药业有限公司 | Compound preparation for treating viral liver disease |
CN113952463A (en) * | 2021-09-30 | 2022-01-21 | 宿州学院 | Nano diagnosis and treatment agent and preparation method and application thereof |
CN114588271A (en) * | 2022-03-15 | 2022-06-07 | 北京理工大学 | Metal-drug full-activity nano-drug and preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
-
2022
- 2022-06-30 CN CN202210769044.5A patent/CN115120561B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1518983A (en) * | 2003-01-22 | 2004-08-11 | 赖庆莲 | Coordinated modication combination for anti hepatitis B virus |
CN1895671A (en) * | 2005-12-08 | 2007-01-17 | 淮北市辉克药业有限公司 | Compound preparation for treating viral liver disease |
CN113952463A (en) * | 2021-09-30 | 2022-01-21 | 宿州学院 | Nano diagnosis and treatment agent and preparation method and application thereof |
CN114588271A (en) * | 2022-03-15 | 2022-06-07 | 北京理工大学 | Metal-drug full-activity nano-drug and preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
Nanotechnology approaches for global infectious diseases;Ameya R. Kirtane 等;《Nature Nanotechnology》;第369-390页 * |
金类配合物的抗肿瘤活性研究进展;祁欢欢等;《药学进展》;第37卷(第6期);265-273 * |
Also Published As
Publication number | Publication date |
---|---|
CN115120561A (en) | 2022-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104225609B (en) | A kind of inflammation targeted neutrophil leucocyte delivery system and its application | |
CN105030795B (en) | A kind of nano medicament carrying system and its preparation method and application | |
CN1390143A (en) | Amphiphilic prodrugs | |
Zhu et al. | Preparation, characterization, and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles | |
CN109350748A (en) | Redox sensitive key bridging small molecule prodrugs and its self-assembled nanometer grain | |
WO2015058664A1 (en) | Use of icariin in preparing medicine for preventing or treating decrease in blood cells | |
CN112516329B (en) | Self-assembled combined drug carrier based on macromolecule prodrug and application thereof | |
CN105999299A (en) | Small-molecular micelle drug-loaded nano-system, as well as preparation method and application thereof | |
CA2449856C (en) | Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells | |
Sung et al. | Preparation and characterization of ginger lipid-derived nanoparticles for colon-targeted siRNA delivery | |
CN110665009B (en) | Nanometer gemcitabine for promoting normalization of tumor blood vessels and application thereof | |
CN111001006A (en) | Curbitacin B and oxidation response antitumor prodrug co-carried bionic nanoparticle | |
CN106361724B (en) | A sustained release nanometer microsphere composition of 20(R) -ginsenoside Rg3 and its preparation method | |
CN115120561B (en) | Combined medicine metal organic hybridization nano assembly and application thereof | |
CN111793147B (en) | Modified chitosan, double-response nano-carrier drug, and preparation method and application thereof | |
CN106317067B (en) | A kind of antitumor medicine conjugate, preparation method, preparation and application | |
CN105770912B (en) | Load medicine ATP sensitive liposome with tumour near-infrared fluorescent image displaying function and preparation method thereof | |
JP2019508388A (en) | Use of fullerenes / metalfullerenes in the manufacture of a medicament for treating myelosuppression | |
CN104045823A (en) | Glycyrrhetinic acid derivative, and preparation method and application thereof | |
Hao et al. | Manganese doped nanosystem for degrading neutrophil extracellular traps and improving chemotherapy efficiency to synergistically inhibit lung metastasis of breast cancer | |
CN108619528A (en) | A kind of cyclodextrin-mesoporous silicon multifunctional nano load medicine particle | |
CN112741828B (en) | Drug combination and preparation method and application thereof | |
EP1568379A1 (en) | Medicinal preparation having chemotherapeutic encapsulated therein | |
Hong et al. | Tumor microenvironment responded naturally extracted FOF1-ATPase loaded chromatophores for antitumor therapy | |
CN108888628B (en) | Application of ginsenoside GRh2 in preparing anti-toxoplasma gondii compound preparation and medicine thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |